These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27902617)

  • 1. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature.
    Narváez J; García-Gómez C; Álvarez L; Santo P; Aparicio M; Pascual M; López de Recalde M; Borrell H; Nolla JM
    Medicine (Baltimore); 2016 Nov; 95(48):e5511. PubMed ID: 27902617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of bosentan in the treatment of ischemic lesions in a case of thromboangiitis obliterans (Buerger disease): a case report.
    Palomo-Arellano A; Cervigón-González I; Torres-Iglesias LM
    Dermatol Online J; 2011 Jul; 17(7):4. PubMed ID: 21810389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan.
    De Haro J; Acin F; Bleda S; Varela C; Esparza L
    BMC Cardiovasc Disord; 2012 Feb; 12():5. PubMed ID: 22333218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of thromboangiitis obliterans (Buerger's disease) with high-potency vasodilators.
    Jiménez-Gallo D; Albarrán-Planelles C; Arjona-Aguilera C; Blanco-Sánchez G; Rodríguez-Mateos ME; Linares-Barrios M
    Dermatol Ther; 2015; 28(3):135-9. PubMed ID: 25649782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label study on long-term outcomes of bosentan for treating ulcers in thromboangiitis obliterans (Buerger's disease).
    De Haro J; Bleda S; Acin F
    Int J Cardiol; 2014 Dec; 177(2):529-31. PubMed ID: 25217217
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy of bosentan in the treatment of digital ulcers secondary to thromboangiitis obliterans].
    Prior Á; Rodriguez-Muguruza S; Sanint J; Olivé A
    Med Clin (Barc); 2015 Jul; 145(1):44. PubMed ID: 25433787
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of bosentan in digital ischemic ulcers.
    Todoli Parra JA; Hernández MM; Arrébola López MA
    Ann Vasc Surg; 2010 Jul; 24(5):690.e1-4. PubMed ID: 20579585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboangiitis obliterans (Buerger's disease).
    Klein-Weigel PF; Richter JG
    Vasa; 2014 Sep; 43(5):337-46. PubMed ID: 25147010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of thromboangiitis obliterans.
    Börner C; Heidrich H
    Vasa; 1998 May; 27(2):80-6. PubMed ID: 9612110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Buerger disease (thromboangiitis obliterans) with bosentan: a case report.
    De Haro J; Florez A; Fernandez JL; Acin F
    BMJ Case Rep; 2009; 2009():. PubMed ID: 21686681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors.
    Abeles AM; Nicolescu M; Pinchover Z; Abeles M
    Vascular; 2014 Aug; 22(4):313-6. PubMed ID: 24000082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease).
    Hooten WM; Bruns HK; Hays JT
    Mayo Clin Proc; 1998 Jun; 73(6):529-32. PubMed ID: 9621859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan in clinical practice for treating digital and other ischemic ulcers in Spanish patients with systemic sclerosis: IBER-DU cohort study.
    Roman Ivorra JA; Simeon CP; Alegre Sancho JJ; Egurbide MV; Castillo MJ; Lloria X; Fonollosa V
    J Rheumatol; 2011 Aug; 38(8):1631-5. PubMed ID: 21632679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive Transcutaneous Monitoring in Long-Term Follow-Up of Patients With Thromboangiitis Obliterans Treated With Intravenous Iloprost.
    Melillo E; Grigoratos C; Sanctis FD; Spontoni P; Nuti M; Dell'Omodarme M; Ferrari M; Balbarini A
    Angiology; 2015 Jul; 66(6):531-8. PubMed ID: 25005765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term (5 years) effects of bosentan in patients with pulmonary arterial hypertension.
    Avellana P; Segovia J; Sufrate E; Gómez-Bueno M; García-Cosío Carmena MD; García-Pavía P; Gutiérrez Landaluce C; Pérez Pereira E; Alonso-Pulpón L
    Rev Esp Cardiol; 2011 Aug; 64(8):667-73. PubMed ID: 21719181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review].
    Hao H; Zhang M; Zhang G; Zhu H; Bao W
    Zhongguo Fei Ai Za Zhi; 2020 Jan; 23(1):60-64. PubMed ID: 31948540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bosentan for digital ulcers in patients with systemic sclerosis.
    Nagai Y; Hasegawa M; Hattori T; Okada E; Tago O; Ishikawa O
    J Dermatol; 2012 Jan; 39(1):48-51. PubMed ID: 21955007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Hatano M; Tamaki Z; Tomita M; Kawashima T; Miyazaki M; Sumida H; Akamata K; Takahashi T; Ichimura Y; Toyama T; Sugita M; Noda S; Yao A; Kinugawa K; Sato S
    Br J Dermatol; 2012 Feb; 166(2):417-21. PubMed ID: 21848685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.
    Simonneau G; Galiè N; Jansa P; Meyer GM; Al-Hiti H; Kusic-Pajic A; Lemarié JC; Hoeper MM; Rubin LJ
    Int J Cardiol; 2014 Mar; 172(2):332-9. PubMed ID: 24525158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results.
    Isner JM; Baumgartner I; Rauh G; Schainfeld R; Blair R; Manor O; Razvi S; Symes JF
    J Vasc Surg; 1998 Dec; 28(6):964-73; discussion 73-5. PubMed ID: 9845647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.